Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ALEXANDER G RAUFI

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1124461181
CMS profile
4227202
Location
PROVIDENCE, RI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$153.49

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $153.49 3

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $107.00 2
Genentech USA, Inc. $46.49 1

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ALEXANDER G RAUFI

NPI 1124461181 · CMS profile ID 4227202

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

PROVIDENCE, RI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1124461181?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ALEXANDER G RAUFI, NPI 1124461181, CMS profile ID 4227202. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1124461181?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ALEXANDER G RAUFI, NPI 1124461181, CMS profile ID 4227202. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1124461181?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ALEXANDER G RAUFI, NPI 1124461181, CMS profile ID 4227202, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1124461181?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $153.49 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Genentech USA, Inc. $46.4906/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132973831 CMS
AstraZeneca Pharmaceuticals LP $35.0005/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104231739 CMS
AstraZeneca Pharmaceuticals LP $72.0001/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104530564 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $275.98 3
PY2023 $71.49 1
PY2024 $153.49 3
PY2025 $279.97 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,095,720.78 205
PY2024 Principal investigator $571,268.16 95

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

205 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $1,913.60 12/17/2025 Covered Recipient Teaching Hospital
Rhode Island Hospital
Phase 2 Study of Autogene Cevumeran in Adjuvant PDAC No dispute reported 06/30/2026 1211553613
Principal investigator 1 Genentech, Inc. $58,655.00 12/17/2025 Covered Recipient Teaching Hospital
Rhode Island Hospital
Phase 2 Study of Autogene Cevumeran in Adjuvant PDAC No dispute reported 06/30/2026 1211553617
Principal investigator 1 Genentech, Inc. $52,046.80 12/17/2025 Covered Recipient Teaching Hospital
Rhode Island Hospital
Phase 2 Study of Autogene Cevumeran in Adjuvant PDAC No dispute reported 06/30/2026 1211553622
Principal investigator 1 Genentech, Inc. $750.00 12/12/2025 Covered Recipient Teaching Hospital
Rhode Island Hospital
Phase 2 Study of Autogene Cevumeran in Adjuvant PDAC No dispute reported 06/30/2026 1211553630
Principal investigator 1 Genentech, Inc. $14,300.00 12/01/2025 Covered Recipient Teaching Hospital
Rhode Island Hospital
Phase 2 Study of Autogene Cevumeran in Adjuvant PDAC No dispute reported 06/30/2026 1211553626
Principal investigator 1 ABBVIE INC. $250.00 11/19/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202420184
Principal investigator 1 ABBVIE INC. $1,300.00 11/19/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202420188
Principal investigator 1 ABBVIE INC. $1,300.00 11/19/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202420191
Principal investigator 1 ABBVIE INC. $1,982.50 11/19/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202420196
Principal investigator 1 Genentech, Inc. $2,141.10 11/19/2025 Covered Recipient Teaching Hospital
Rhode Island Hospital
Phase 2 Study of Autogene Cevumeran in Adjuvant PDAC No dispute reported 06/30/2026 1211553599
Principal investigator 1 Genentech, Inc. $404.30 11/19/2025 Covered Recipient Teaching Hospital
Rhode Island Hospital
Phase 2 Study of Autogene Cevumeran in Adjuvant PDAC No dispute reported 06/30/2026 1211553603
Principal investigator 1 Genentech, Inc. $1,500.00 11/19/2025 Covered Recipient Teaching Hospital
Rhode Island Hospital
Phase 2 Study of Autogene Cevumeran in Adjuvant PDAC No dispute reported 06/30/2026 1211553609
Principal investigator 1 AstraZeneca Pharmaceuticals LP $33,090.00 10/31/2025 Covered Recipient Teaching Hospital
Rhode Island Hospital
A Phase I II Open label Dose Escalation and Dose Expansion Study to Evaluate the Safety Pharmacokinetics Pharmacodynamics and Efficacy of AZD4360 a TOP1i ADC Targeting Claudin 18 2 CLDN18 2 in Adult Participants with Advanced Solid Tumours No dispute reported 06/30/2026 1185552937
Principal investigator 1 Genentech, Inc. $1,976.00 10/17/2025 Covered Recipient Teaching Hospital
Rhode Island Hospital
Phase 2 Study of Autogene Cevumeran in Adjuvant PDAC No dispute reported 06/30/2026 1211553586
Principal investigator 1 Genentech, Inc. $1,751.10 10/01/2025 Covered Recipient Teaching Hospital
Rhode Island Hospital
Phase 2 Study of Autogene Cevumeran in Adjuvant PDAC No dispute reported 06/30/2026 1211553573
Principal investigator 1 Genentech, Inc. $21,115.00 10/01/2025 Covered Recipient Teaching Hospital
Rhode Island Hospital
Phase 2 Study of Autogene Cevumeran in Adjuvant PDAC No dispute reported 06/30/2026 1211553579
Principal investigator 1 Genentech, Inc. $5,987.80 10/01/2025 Covered Recipient Teaching Hospital
Rhode Island Hospital
Phase 2 Study of Autogene Cevumeran in Adjuvant PDAC No dispute reported 06/30/2026 1211553583
Principal investigator 1 Genentech, Inc. $21,918.00 10/01/2025 Covered Recipient Teaching Hospital
Rhode Island Hospital
Phase 2 Study of Autogene Cevumeran in Adjuvant PDAC No dispute reported 06/30/2026 1211553589
Principal investigator 1 Genentech, Inc. $2,343.90 10/01/2025 Covered Recipient Teaching Hospital
Rhode Island Hospital
Phase 2 Study of Autogene Cevumeran in Adjuvant PDAC No dispute reported 06/30/2026 1211553592
Principal investigator 1 ABBVIE INC. $3,113.50 09/29/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202420136
Principal investigator 1 ABBVIE INC. $1,817.40 09/29/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202420140
Principal investigator 1 ABBVIE INC. $4,071.60 09/29/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202420143
Principal investigator 1 ABBVIE INC. $975.00 09/10/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202420122
Principal investigator 1 ABBVIE INC. $13,500.00 09/03/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202420082
Principal investigator 1 ABBVIE INC. $5,100.00 09/03/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202420086
Principal investigator 1 ABBVIE INC. $1,950.00 09/03/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202420089
Principal investigator 1 ABBVIE INC. $2,000.00 09/03/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202420093
Principal investigator 1 ABBVIE INC. $1,000.00 09/03/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202420096
Principal investigator 1 ABBVIE INC. $750.00 09/03/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202420099
Principal investigator 1 ABBVIE INC. $1,300.00 09/03/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202420104
Principal investigator 1 ABBVIE INC. $2,080.00 09/03/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202420108
Principal investigator 1 ABBVIE INC. $14,300.00 09/03/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202420112
Principal investigator 1 ABBVIE INC. $1,170.00 09/03/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202420115
Principal investigator 1 ABBVIE INC. $1,682.20 08/29/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202420075
Principal investigator 1 ABBVIE INC. $1,200.00 08/28/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202420023
Principal investigator 1 ABBVIE INC. $2,155.40 08/28/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202420027
Principal investigator 1 ABBVIE INC. $730.60 08/28/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202420031
Principal investigator 1 ABBVIE INC. $2,155.40 08/28/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202420035
Principal investigator 1 ABBVIE INC. $2,155.40 08/28/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202420039
Principal investigator 1 ABBVIE INC. $2,155.40 08/28/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202420043
Principal investigator 1 ABBVIE INC. $2,155.40 08/28/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202420046
Principal investigator 1 ABBVIE INC. $2,155.40 08/28/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202420050
Principal investigator 1 ABBVIE INC. $780.00 08/28/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202420054
Principal investigator 1 ABBVIE INC. $365.30 08/28/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202420059
Principal investigator 1 ABBVIE INC. $2,155.40 08/28/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202420063
Principal investigator 1 ABBVIE INC. $2,155.40 08/28/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202420067
Principal investigator 1 ABBVIE INC. $2,155.40 08/28/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202420071
Principal investigator 1 Genentech, Inc. $7,205.90 08/15/2025 Covered Recipient Teaching Hospital
Rhode Island Hospital
Phase 2 Study of Autogene Cevumeran in Adjuvant PDAC No dispute reported 06/30/2026 1211553529
Principal investigator 1 Genentech, Inc. $11,939.20 07/25/2025 Covered Recipient Teaching Hospital
Rhode Island Hospital
Phase 2 Study of Autogene Cevumeran in Adjuvant PDAC No dispute reported 06/30/2026 1211553544
Principal investigator 1 Genentech, Inc. $842.40 07/18/2025 Covered Recipient Teaching Hospital
Rhode Island Hospital
Phase 2 Study of Autogene Cevumeran in Adjuvant PDAC No dispute reported 06/30/2026 1211553562
Principal investigator 1 Genentech, Inc. $17,683.90 07/16/2025 Covered Recipient Teaching Hospital
Rhode Island Hospital
Phase 2 Study of Autogene Cevumeran in Adjuvant PDAC No dispute reported 06/30/2026 1211553566
Principal investigator 1 Genentech, Inc. $932.10 07/11/2025 Covered Recipient Teaching Hospital
Rhode Island Hospital
Phase 2 Study of Autogene Cevumeran in Adjuvant PDAC No dispute reported 06/30/2026 1211553570
Principal investigator 1 Genentech, Inc. $949.00 07/09/2025 Covered Recipient Teaching Hospital
Rhode Island Hospital
Phase 2 Study of Autogene Cevumeran in Adjuvant PDAC No dispute reported 06/30/2026 1211553533
Principal investigator 1 Genentech, Inc. $390.00 07/09/2025 Covered Recipient Teaching Hospital
Rhode Island Hospital
Phase 2 Study of Autogene Cevumeran in Adjuvant PDAC No dispute reported 06/30/2026 1211553537
Principal investigator 1 Genentech, Inc. $332.80 07/09/2025 Covered Recipient Teaching Hospital
Rhode Island Hospital
Phase 2 Study of Autogene Cevumeran in Adjuvant PDAC No dispute reported 06/30/2026 1211553549
Principal investigator 1 Genentech, Inc. $404.30 07/09/2025 Covered Recipient Teaching Hospital
Rhode Island Hospital
Phase 2 Study of Autogene Cevumeran in Adjuvant PDAC No dispute reported 06/30/2026 1211553554
Principal investigator 1 Genentech, Inc. $18,608.20 07/09/2025 Covered Recipient Teaching Hospital
Rhode Island Hospital
Phase 2 Study of Autogene Cevumeran in Adjuvant PDAC No dispute reported 06/30/2026 1211553558
Principal investigator 1 Genentech, Inc. $6,949.80 07/02/2025 Covered Recipient Teaching Hospital
Rhode Island Hospital
Phase 2 Study of Autogene Cevumeran in Adjuvant PDAC No dispute reported 06/30/2026 1211553540
Principal investigator 1 ABBVIE INC. $2,362.10 06/27/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419951
Principal investigator 1 ABBVIE INC. $1,682.20 06/27/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419956
Principal investigator 1 ABBVIE INC. $3,070.60 06/27/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419959
Principal investigator 1 ABBVIE INC. $12,932.40 06/20/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419888
Principal investigator 1 ABBVIE INC. $2,155.40 06/20/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419892
Principal investigator 1 ABBVIE INC. $8,621.60 06/20/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419895
Principal investigator 1 ABBVIE INC. $2,155.40 06/20/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419898
Principal investigator 1 ABBVIE INC. $1,461.20 06/20/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419902
Principal investigator 1 ABBVIE INC. $2,155.40 06/20/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419906
Principal investigator 1 ABBVIE INC. $1,170.00 06/20/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419910
Principal investigator 1 ABBVIE INC. $8,621.60 06/20/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419914
Principal investigator 1 ABBVIE INC. $2,155.40 06/20/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419918
Principal investigator 1 ABBVIE INC. $2,155.40 06/20/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419923
Principal investigator 1 ABBVIE INC. $365.30 06/20/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419927
Principal investigator 1 ABBVIE INC. $2,155.40 06/20/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419931
Principal investigator 1 ABBVIE INC. $780.00 06/20/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419935
Principal investigator 1 ABBVIE INC. $10,777.00 06/20/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419939
Principal investigator 1 ABBVIE INC. $8,621.60 06/20/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419943
Principal investigator 1 ABBVIE INC. $390.00 06/20/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419947
Principal investigator 1 Sirtex Medical Inc $21,839.07 06/10/2025 Covered Recipient Teaching Hospital
Rhode Island Hospital
Y-90 Capecitabine and Atezolizumab for Oligometastatic CRC (METEORITE) No dispute reported 06/30/2026 1246170565
Principal investigator 1 Genentech, Inc. $500.00 06/04/2025 Covered Recipient Teaching Hospital
Rhode Island Hospital
Phase 2 Study of Autogene Cevumeran in Adjuvant PDAC No dispute reported 06/30/2026 1211553497
Principal investigator 1 Genentech, Inc. $36,590.00 06/04/2025 Covered Recipient Teaching Hospital
Rhode Island Hospital
Phase 2 Study of Autogene Cevumeran in Adjuvant PDAC No dispute reported 06/30/2026 1211553501
Principal investigator 1 Genentech, Inc. $1,263.60 06/04/2025 Covered Recipient Teaching Hospital
Rhode Island Hospital
Phase 2 Study of Autogene Cevumeran in Adjuvant PDAC No dispute reported 06/30/2026 1211553505
Principal investigator 1 ABBVIE INC. $2,947.10 05/28/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419834
Principal investigator 1 ABBVIE INC. $3,070.60 05/28/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419838
Principal investigator 1 ABBVIE INC. $2,918.50 05/28/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419842
Principal investigator 1 ABBVIE INC. $2,362.10 05/28/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419846
Principal investigator 1 ABBVIE INC. $2,362.10 05/28/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419849
Principal investigator 1 ABBVIE INC. $2,947.10 05/28/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419854
Principal investigator 1 ABBVIE INC. $1,817.40 05/28/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419857
Principal investigator 1 ABBVIE INC. $2,017.60 05/28/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419861
Principal investigator 1 ABBVIE INC. $2,155.40 05/23/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419815
Principal investigator 1 ABBVIE INC. $6,466.20 05/23/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419818
Principal investigator 1 ABBVIE INC. $2,155.40 05/23/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419822
Principal investigator 1 ABBVIE INC. $365.30 05/23/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419826
Principal investigator 1 ABBVIE INC. $2,155.40 05/23/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419831
Principal investigator 1 ABBVIE INC. $400.40 05/22/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419788
Principal investigator 1 ABBVIE INC. $97.50 05/22/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419792
Principal investigator 1 ABBVIE INC. $6,500.00 05/22/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419796
Principal investigator 1 ABBVIE INC. $2,155.40 05/22/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419800
Principal investigator 1 ABBVIE INC. $2,155.40 05/22/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419803
Principal investigator 1 ABBVIE INC. $2,155.40 05/22/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419807
Principal investigator 1 ABBVIE INC. $365.30 05/22/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419811
Principal investigator 1 ABBVIE INC. $6,466.20 05/15/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419762
Principal investigator 1 ABBVIE INC. $4,250.00 05/15/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419765
Principal investigator 1 ABBVIE INC. $11,700.00 05/15/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419769
Principal investigator 1 ABBVIE INC. $5,070.00 05/15/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419772
Principal investigator 1 ABBVIE INC. $6,500.00 05/15/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419776
Principal investigator 1 ABBVIE INC. $500.00 05/15/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419780
Principal investigator 1 ABBVIE INC. $750.00 05/15/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419784
Principal investigator 1 ABBVIE INC. $2,155.40 05/12/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419745
Principal investigator 1 ABBVIE INC. $2,155.40 05/12/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419750
Principal investigator 1 ABBVIE INC. $3,211.00 04/28/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419733
Principal investigator 1 ABBVIE INC. $4,192.50 03/31/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419717
Principal investigator 1 ABBVIE INC. $1,682.20 03/31/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419721
Principal investigator 1 ABBVIE INC. $2,362.10 03/31/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419725
Principal investigator 1 Genentech, Inc. $78,477.10 03/19/2025 Covered Recipient Teaching Hospital
Rhode Island Hospital
Phase 2 Study of Autogene Cevumeran in Adjuvant PDAC No dispute reported 06/30/2026 1211553493
Principal investigator 1 Sirtex Medical Inc $5,200.00 03/12/2025 Covered Recipient Teaching Hospital
Rhode Island Hospital
Y-90 Capecitabine and Atezolizumab for Oligometastatic CRC (METEORITE) No dispute reported 06/30/2026 1246170563
Principal investigator 1 ABBVIE INC. $2,849.60 02/28/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419676
Principal investigator 1 ABBVIE INC. $2,362.10 02/28/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419679
Principal investigator 1 ABBVIE INC. $2,752.10 01/29/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419652
Principal investigator 1 ABBVIE INC. $3,070.60 01/29/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419656
Principal investigator 1 ABBVIE INC. $2,362.10 01/29/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419660
Principal investigator 1 AstraZeneca Pharmaceuticals LP $237,422.21 01/24/2025 Covered Recipient Teaching Hospital
Rhode Island Hospital
A Phase II Open-label Multi-centre Study to Evaluate Safety Tolerability Efficacy PK and Immunogenicity of AZD0901 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Tumours Expressing Claudin 182 No dispute reported 06/30/2026 1185552939
Principal investigator 1 ABBVIE INC. $500.00 01/22/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419597
Principal investigator 1 ABBVIE INC. $1,500.00 01/22/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419600
Principal investigator 1 ABBVIE INC. $1,500.00 01/22/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419604
Principal investigator 1 ABBVIE INC. $455.00 01/22/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419608
Principal investigator 1 ABBVIE INC. $1,300.00 01/22/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419612
Principal investigator 1 ABBVIE INC. $2,000.00 01/22/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419615
Principal investigator 1 ABBVIE INC. $500.00 01/22/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419620
Principal investigator 1 ABBVIE INC. $500.00 01/22/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419623
Principal investigator 1 ABBVIE INC. $1,950.00 01/22/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419627
Principal investigator 1 ABBVIE INC. $1,700.00 01/22/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419631
Principal investigator 1 ABBVIE INC. $1,300.00 01/22/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419635
Principal investigator 1 ABBVIE INC. $1,300.00 01/22/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419639
Principal investigator 1 ABBVIE INC. $5,100.00 01/22/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419643
Principal investigator 1 ABBVIE INC. $1,000.00 01/22/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419648
Principal investigator 1 ABBVIE INC. $11,700.00 01/20/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419575
Principal investigator 1 ABBVIE INC. $2,155.40 01/20/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419579
Principal investigator 1 ABBVIE INC. $2,155.40 01/20/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419583
Principal investigator 1 ABBVIE INC. $365.30 01/20/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419587
Principal investigator 1 ABBVIE INC. $2,155.40 01/20/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419590
Principal investigator 1 ABBVIE INC. $4,192.50 01/20/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419594
Principal investigator 1 ABBVIE INC. $2,155.40 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419342
Principal investigator 1 ABBVIE INC. $2,155.40 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419346
Principal investigator 1 ABBVIE INC. $365.30 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419349
Principal investigator 1 ABBVIE INC. $2,155.40 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419352
Principal investigator 1 ABBVIE INC. $2,155.40 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419356
Principal investigator 1 ABBVIE INC. $400.40 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419358
Principal investigator 1 ABBVIE INC. $2,155.40 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419362
Principal investigator 1 ABBVIE INC. $2,155.40 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419365
Principal investigator 1 ABBVIE INC. $365.30 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419368
Principal investigator 1 ABBVIE INC. $365.30 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419372
Principal investigator 1 ABBVIE INC. $365.30 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419376
Principal investigator 1 ABBVIE INC. $6,500.00 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419380
Principal investigator 1 ABBVIE INC. $2,155.40 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419383
Principal investigator 1 ABBVIE INC. $2,155.40 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419387
Principal investigator 1 ABBVIE INC. $2,155.40 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419391
Principal investigator 1 ABBVIE INC. $2,155.40 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419394
Principal investigator 1 ABBVIE INC. $2,155.40 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419399
Principal investigator 1 ABBVIE INC. $97.50 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419403
Principal investigator 1 ABBVIE INC. $2,155.40 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419407
Principal investigator 1 ABBVIE INC. $2,155.40 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419410
Principal investigator 1 ABBVIE INC. $2,155.40 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419415
Principal investigator 1 ABBVIE INC. $2,155.40 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419418
Principal investigator 1 ABBVIE INC. $6,500.00 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419421
Principal investigator 1 ABBVIE INC. $365.30 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419425
Principal investigator 1 ABBVIE INC. $365.30 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419429
Principal investigator 1 ABBVIE INC. $2,155.40 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419433
Principal investigator 1 ABBVIE INC. $2,155.40 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419438
Principal investigator 1 ABBVIE INC. $365.30 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419442
Principal investigator 1 ABBVIE INC. $2,155.40 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419445
Principal investigator 1 ABBVIE INC. $2,155.40 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419449
Principal investigator 1 ABBVIE INC. $6,500.00 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419453
Principal investigator 1 ABBVIE INC. $2,155.40 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419457
Principal investigator 1 ABBVIE INC. $2,155.40 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419461
Principal investigator 1 ABBVIE INC. $2,155.40 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419465
Principal investigator 1 ABBVIE INC. $2,155.40 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419469
Principal investigator 1 ABBVIE INC. $730.60 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419473
Principal investigator 1 ABBVIE INC. $2,155.40 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419477
Principal investigator 1 ABBVIE INC. $2,155.40 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419480
Principal investigator 1 ABBVIE INC. $2,155.40 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419484
Principal investigator 1 ABBVIE INC. $2,155.40 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419487
Principal investigator 1 ABBVIE INC. $2,155.40 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419490
Principal investigator 1 ABBVIE INC. $2,155.40 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419494
Principal investigator 1 ABBVIE INC. $97.50 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419498
Principal investigator 1 ABBVIE INC. $365.30 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419501
Principal investigator 1 ABBVIE INC. $400.40 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419505
Principal investigator 1 ABBVIE INC. $400.40 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419509
Principal investigator 1 ABBVIE INC. $2,155.40 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419512
Principal investigator 1 ABBVIE INC. $2,155.40 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419516
Principal investigator 1 ABBVIE INC. $6,500.00 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419520
Principal investigator 1 ABBVIE INC. $97.50 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419523
Principal investigator 1 ABBVIE INC. $2,155.40 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419527
Principal investigator 1 ABBVIE INC. $2,155.40 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419530
Principal investigator 1 ABBVIE INC. $2,155.40 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419533
Principal investigator 1 ABBVIE INC. $400.40 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419537
Principal investigator 1 ABBVIE INC. $365.30 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419542
Principal investigator 1 ABBVIE INC. $2,155.40 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419544
Principal investigator 1 ABBVIE INC. $2,155.40 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419548
Principal investigator 1 ABBVIE INC. $365.30 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419552
Principal investigator 1 ABBVIE INC. $400.40 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419557
Principal investigator 1 ABBVIE INC. $2,155.40 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419560
Principal investigator 1 ABBVIE INC. $365.30 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419563
Principal investigator 1 ABBVIE INC. $2,155.40 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419567
Principal investigator 1 ABBVIE INC. $2,155.40 01/16/2025 Covered Recipient Teaching Hospital
RHODE ISLAND HOSPITAL
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 1202419571